TSE:WLLW

Willow Biosciences Inc. (WLLW.TO) Competitors

C$1.32

-0.01 (-0.75 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

C$1.26

Now: C$1.32▼

C$1.34

50-Day Range

C$1.29

MA: C$1.48▼

C$1.80

52-Week Range

C$0.29

Now: C$1.32▼

C$2.24

Volume124,217 shs

Average Volume476,683 shs

Market CapitalizationC$162.10 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) Vs. RIV, LABS, KHRN, DN, META, and NRTH

Should you be buying WLLW stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to Willow Biosciences Inc. (WLLW.TO), including RIV Capital (RIV), MediPharm Labs (LABS), Khiron Life Sciences (KHRN), Delta 9 Cannabis (DN), Meta Growth (META), and 48North Cannabis (NRTH).

Willow Biosciences Inc. (WLLW.TO) vs. RIV Capital Stock

Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) and RIV Capital (TSE:RIV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Willow Biosciences Inc. (WLLW.TO) and RIV Capital, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Willow Biosciences Inc. (WLLW.TO)	0	0	0	0	N/A
RIV Capital	0	1	0	0	2.00

Willow Biosciences Inc. (WLLW.TO) presently has a consensus price target of C$2.25, indicating a potential upside of 71.10%. RIV Capital has a consensus price target of C$4.00, indicating a potential upside of 90.48%. Given RIV Capital's higher possible upside, analysts clearly believe RIV Capital is more favorable than Willow Biosciences Inc. (WLLW.TO).

Valuation & Earnings

This table compares Willow Biosciences Inc. (WLLW.TO) and RIV Capital's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Willow Biosciences Inc. (WLLW.TO)	C$10,000.00	16,209.74	C$-51,032,952.00	C($0.41)	-3.18
RIV Capital	C$15.44 million	19.03	C$-106,223,568.00	C($0.76)	-2.77

Willow Biosciences Inc. (WLLW.TO) has higher earnings, but lower revenue than RIV Capital. Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than RIV Capital, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Willow Biosciences Inc. (WLLW.TO) and RIV Capital's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Willow Biosciences Inc. (WLLW.TO)	N/A	N/A	N/A
RIV Capital	N/A	N/A	N/A

Willow Biosciences Inc. (WLLW.TO) vs. MediPharm Labs Stock

Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Willow Biosciences Inc. (WLLW.TO) and MediPharm Labs' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Willow Biosciences Inc. (WLLW.TO)	N/A	N/A	N/A
MediPharm Labs	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations for Willow Biosciences Inc. (WLLW.TO) and MediPharm Labs, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Willow Biosciences Inc. (WLLW.TO)	0	0	0	0	N/A
MediPharm Labs	0	2	0	2	3.00

Willow Biosciences Inc. (WLLW.TO) presently has a consensus target price of C$2.25, suggesting a potential upside of 71.10%. MediPharm Labs has a consensus target price of C$1.53, suggesting a potential upside of 225.53%. Given MediPharm Labs' higher possible upside, analysts plainly believe MediPharm Labs is more favorable than Willow Biosciences Inc. (WLLW.TO).

Earnings & Valuation

This table compares Willow Biosciences Inc. (WLLW.TO) and MediPharm Labs' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Willow Biosciences Inc. (WLLW.TO)	C$10,000.00	16,209.74	C$-51,032,952.00	C($0.41)	-3.18
MediPharm Labs	C$36.01 million	3.37	C$-123,815,040.00	C($0.48)	-0.98

Willow Biosciences Inc. (WLLW.TO) has higher earnings, but lower revenue than MediPharm Labs. Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Summary

MediPharm Labs beats Willow Biosciences Inc. (WLLW.TO) on 4 of the 7 factors compared between the two stocks.

Willow Biosciences Inc. (WLLW.TO) vs. Khiron Life Sciences Stock

Khiron Life Sciences (CVE:KHRN) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Khiron Life Sciences and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Khiron Life Sciences	N/A	N/A	N/A
Willow Biosciences Inc. (WLLW.TO)	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Khiron Life Sciences and Willow Biosciences Inc. (WLLW.TO), as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Khiron Life Sciences	0	0	0	0	N/A
Willow Biosciences Inc. (WLLW.TO)	0	0	0	0	N/A

Khiron Life Sciences presently has a consensus price target of C$1.20, suggesting a potential upside of 130.77%. Willow Biosciences Inc. (WLLW.TO) has a consensus price target of C$2.25, suggesting a potential upside of 71.10%. Given Khiron Life Sciences' higher probable upside, equities research analysts clearly believe Khiron Life Sciences is more favorable than Willow Biosciences Inc. (WLLW.TO).

Valuation and Earnings

This table compares Khiron Life Sciences and Willow Biosciences Inc. (WLLW.TO)'s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Khiron Life Sciences	C$8.01 million	9.75	C$-39,493,921.00	C($0.26)	-1.98
Willow Biosciences Inc. (WLLW.TO)	C$10,000.00	16,209.74	C$-51,032,952.00	C($0.41)	-3.18

Khiron Life Sciences has higher revenue and earnings than Willow Biosciences Inc. (WLLW.TO). Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than Khiron Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Khiron Life Sciences beats Willow Biosciences Inc. (WLLW.TO) on 5 of the 6 factors compared between the two stocks.

Willow Biosciences Inc. (WLLW.TO) vs. Delta 9 Cannabis Stock

Delta 9 Cannabis (TSE:DN) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Delta 9 Cannabis and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Delta 9 Cannabis	N/A	N/A	N/A
Willow Biosciences Inc. (WLLW.TO)	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Delta 9 Cannabis and Willow Biosciences Inc. (WLLW.TO), as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delta 9 Cannabis	0	0	0	1	4.00
Willow Biosciences Inc. (WLLW.TO)	0	0	0	0	N/A

Delta 9 Cannabis currently has a consensus price target of C$1.10, suggesting a potential upside of 89.66%. Willow Biosciences Inc. (WLLW.TO) has a consensus price target of C$2.25, suggesting a potential upside of 71.10%. Given Delta 9 Cannabis' higher probable upside, analysts clearly believe Delta 9 Cannabis is more favorable than Willow Biosciences Inc. (WLLW.TO).

Earnings & Valuation

This table compares Delta 9 Cannabis and Willow Biosciences Inc. (WLLW.TO)'s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delta 9 Cannabis	C$52.05 million	1.14	C$-7,346,808.00	C($0.07)	-8.06
Willow Biosciences Inc. (WLLW.TO)	C$10,000.00	16,209.74	C$-51,032,952.00	C($0.41)	-3.18

Delta 9 Cannabis has higher revenue and earnings than Willow Biosciences Inc. (WLLW.TO). Delta 9 Cannabis is trading at a lower price-to-earnings ratio than Willow Biosciences Inc. (WLLW.TO), indicating that it is currently the more affordable of the two stocks.

Summary

Delta 9 Cannabis beats Willow Biosciences Inc. (WLLW.TO) on 5 of the 7 factors compared between the two stocks.

Willow Biosciences Inc. (WLLW.TO) vs. Meta Growth Stock

Meta Growth (CVE:META) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares Meta Growth and Willow Biosciences Inc. (WLLW.TO)'s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Meta Growth	C$60.96 million	0.54	C$-50,412,840.00	C($0.21)	-0.66
Willow Biosciences Inc. (WLLW.TO)	C$10,000.00	16,209.74	C$-51,032,952.00	C($0.41)	-3.18

Meta Growth has higher revenue and earnings than Willow Biosciences Inc. (WLLW.TO). Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Meta Growth and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Meta Growth	N/A	N/A	N/A
Willow Biosciences Inc. (WLLW.TO)	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Meta Growth and Willow Biosciences Inc. (WLLW.TO), as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Meta Growth	0	0	0	0	N/A
Willow Biosciences Inc. (WLLW.TO)	0	0	0	0	N/A

Willow Biosciences Inc. (WLLW.TO) has a consensus price target of C$2.25, suggesting a potential upside of 71.10%. Given Willow Biosciences Inc. (WLLW.TO)'s higher probable upside, analysts plainly believe Willow Biosciences Inc. (WLLW.TO) is more favorable than Meta Growth.

Summary

Meta Growth beats Willow Biosciences Inc. (WLLW.TO) on 4 of the 6 factors compared between the two stocks.

Willow Biosciences Inc. (WLLW.TO) vs. 48North Cannabis Stock

48North Cannabis (CVE:NRTH) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for 48North Cannabis and Willow Biosciences Inc. (WLLW.TO), as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
48North Cannabis	0	0	0	0	N/A
Willow Biosciences Inc. (WLLW.TO)	0	0	0	0	N/A

Willow Biosciences Inc. (WLLW.TO) has a consensus target price of C$2.25, suggesting a potential upside of 71.10%. Given Willow Biosciences Inc. (WLLW.TO)'s higher probable upside, analysts clearly believe Willow Biosciences Inc. (WLLW.TO) is more favorable than 48North Cannabis.

Earnings and Valuation

This table compares 48North Cannabis and Willow Biosciences Inc. (WLLW.TO)'s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
48North Cannabis	C$17.36 million	1.84	C$-52,460,873.00	C($0.26)	-0.61
Willow Biosciences Inc. (WLLW.TO)	C$10,000.00	16,209.74	C$-51,032,952.00	C($0.41)	-3.18

Willow Biosciences Inc. (WLLW.TO) has lower revenue, but higher earnings than 48North Cannabis. Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares 48North Cannabis and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
48North Cannabis	N/A	N/A	N/A
Willow Biosciences Inc. (WLLW.TO)	N/A	N/A	N/A